OncoResponse leverages the power of the human immune system to identify fully human monoclonal antibodies and discover novel targets that will lead to the development of antibody-derived therapeutics for the treatment of cancer. Through our partnership with MD Anderson Cancer Center, we deploy a unique and transformative approach to the discovery of cancer therapeutics. OncoResponse is based in Seattle, Washington.